Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Pharming Group N.V. is a commercial-stage biotechnology company focused on developing and commercializing therapies for rare diseases with significant unmet medical need. The company operates within the biopharmaceutical industry, with a particular emphasis on rare and ultra-rare genetic disorders. Pharming’s core revenue is generated from approved prescription medicines, supported by in-house development capabilities and selective licensing strategies.
The company’s primary products include Ruconest® (conestat alfa), a recombinant human C1 esterase inhibitor used for the treatment of acute hereditary angioedema (HAE) attacks, and Joenja® (leniolisib), an oral small-molecule therapy approved for activated phosphoinositide 3-kinase delta syndrome (APDS). Pharming serves specialist physicians, hospitals, and rare-disease treatment centers, primarily in North America and Europe. Founded in 1988, the company evolved from an early-stage biotech into a revenue-generating rare-disease company following regulatory approvals and the build-out of its commercial infrastructure.
Business Operations
Pharming operates through two principal business segments: Commercial Products and Research & Development. The Commercial Products segment generates revenue through the sale of Ruconest® and Joenja®, with the United States representing the largest single market. The Research & Development segment focuses on expanding indications for existing products and advancing earlier-stage clinical programs targeting immune and genetic disorders.
The company controls proprietary technologies, including a transgenic production platform that uses genetically modified rabbits to produce recombinant human proteins. Pharming conducts operations through subsidiaries such as Pharming Technologies B.V. and Pharming Healthcare, Inc., which manage manufacturing, regulatory, and commercial activities. Commercial distribution in the U.S. is handled directly, while certain international markets rely on partners and distributors.
Strategic Position & Investments
Pharming’s strategic direction centers on becoming a leading rare-disease company by maximizing the value of its existing commercial assets while expanding its pipeline through targeted internal development and external opportunities. A major strategic milestone was the acquisition of global development and commercialization rights to Joenja® (leniolisib) from Novartis AG, which significantly broadened Pharming’s disease focus beyond HAE.
The company continues to invest in lifecycle management for Ruconest®, including exploration of additional indications, while advancing follow-on clinical studies for Joenja® in related immune disorders. Pharming has stated that it actively evaluates acquisitions, in-licensing opportunities, and partnerships that align with its rare-disease focus. No material joint ventures have been publicly disclosed beyond licensing and distribution arrangements.
Geographic Footprint
Pharming Group N.V. is headquartered in Leiden, the Netherlands, with its primary commercial operations based in the United States, which accounts for the majority of revenue. The company maintains a direct presence across North America and Europe, supported by regulatory approvals in multiple jurisdictions.
Beyond its core markets, Pharming has commercial or named-patient access in parts of Asia-Pacific, Latin America, and the Middle East, primarily through regional partners. Manufacturing activities are largely Europe-based, while clinical development and commercial infrastructure are globally distributed to support international growth.
Leadership & Governance
Pharming is led by a management team with experience in biotechnology commercialization, rare diseases, and global operations. The company emphasizes a strategic vision focused on sustainable growth, disciplined capital allocation, and long-term value creation for patients and shareholders through innovation in rare diseases.
Key executives include:
- Sijmen de Vries – Chief Executive Officer
- Jeroen Brugman – Chief Financial Officer
- Anurag Relan, MD – Chief Medical Officer
- Eric Hennissen – Chief Operations Officer
- Michel de Jong – Chief Commercial Officer
The company operates under a two-tier governance structure typical of Dutch public companies, with a Management Board responsible for operations and a Supervisory Board providing oversight.